

bps.


Patient Case – Jamie


Jamie is a 78-year-old patient who is complaining of urinary frequency that has gotten worse over the last three months. She states that she often has to run to the restroom to urinate during normal daily activities such as walking in her rose garden, attending small council meetings, and shopping. Even though she has to rush, she has not had any "accidents".


She has two adult children and two grandchildren. She walks with a cane and was a homemaker.


Vital signs include BP 134/88, P 96, T 98.2F, Ht 5'7", Wt 212 lbs. Her annual lab work was unremarkable and her most recent Hgb A1c was 6.4%.

17










<section-header><section-header><section-header><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item>

Reversible Causes & Management (DRIIPP)

Condition	Management		
Delirium	Treat underlying cause		
Restricted mobility, injury, restraint	Scheduled toileting, assistive devices, environment changes		
Infection/Inflammation			
Urinary tract infection	Antibiotics (not asymptomatic bacteriuria)		
Atrophic vaginitis/urethritis	Topical estrogen		
Prostatectomy	Behavioral, no additional surgery within first year		
Stool Impaction	Anti-constipation medications, increase fluid intake, manual disimpaction		
Polyuria			
Metabolic (hyperglycemia, hypercalcemia)	Control diabetes, treat underlying cause		
Excess intake	• Fluid restriction, reduce diuretic fluids (e.g., caffeine)		
Volume overload	Diuretics		
Venous insufficiency/edema	Compression stockings, leg elevation, sodium restriction, diuretics		
Pharmaceuticals	Discontinue, change, decrease dose, timing, polypharmacy		
Geriatric pharmacist	Johnson TM. Handb Clin Neurol. 2019;167:495-509.		

23

Medication-Induced Incontinence				
Stress	 α-blockers 	Atypical antipsychotics		
	ACE inhibitors	Sedative-hypnotics		
	 Antidepressants 	Hormone replacement		
Urge	 5HT₄ (serotonin)-agonists 	 Sodium-glucose cotransporter-2 inhibitors 		
	Direct or indirect parasympathomimetics (cholinesterase inhibitors)			
	Anticholinergics	 α-agonists 		
Overflow	Antiparkinson drugs	Opioids		
	 β-agonists 	Calcium channel blockers		
	Histamine antagonists	Opioids		
Functional	Antipsychotics	Alcohol		
	Benzodiazepines	Antidepressants		
la sue se la la la s	Diuretics	Thiazolidinediones		
Increase Urine Production	• Lithium	Muscle relaxants		
Production	NSAIDs	Alcohol		
ACE – angiotensin-converting enzyme;				
		Johnson TM. Handb Clin Neurol. 2019;167:495-509.		



Classification: Chronic/Persistent UI					
	Urge Stress Overflow Functional				
Cause	Detrusor muscle overactivity	Weakened pelvic floor muscles (e.g., pregnancy, parity)	Bladder distension due to obstruction (BPH, fecal impaction)	Underlying physical or mental impairment impacting ability to toilet	
Common Symptoms	Urgency with or without incontinence, frequency, nocturia or enuresis	Incontinence with coughing, sneezing, laughing, exercise, activities that increase abdominal pressure, frequency	Incomplete voiding, frequency, hesitancy, abdominal fullness, straining	Incontinence – Iooks like urge	
Geriatric phari BOOT C	GERIATRIC PHARMACIST Mixed = usually combination of urge and stress incontinence Guzzo TJ, et al. Med Clin North Am. 2011 Jan;95(1):253-64.				

bps.


Patient Case – Jamie


Jamie is a 78-year-old patient who is complaining of urinary frequency that has gotten worse over the last three months. She states that she often has to run to the restroom to urinate during normal daily activities such as walking in her rose garden, attending small council meetings, and shopping. Even though she has to rush, she has not had any "accidents".


She has two adult children and two grandchildren. She walks with a cane and was a homemaker.


Vital signs include BP 134/88, P 96, T 98.2F, Ht 5'7", Wt 212 lbs. Her annual lab work was unremarkable and her most recent Hgb A1c was 6.4%.

27





















Urge UI Treatment Targets: Non-selective				
Receptor	Anatomical Location Result of Antagonism			
5.04	Brain	Cognitive impairment		
M1	GI tract	Constipation, dry mouth		
	Brain	Cognitive impairment		
M2	Heart	Tachycardia		
	Urinary tract	Bladder relaxation, sphincter closing		
	Urinary tract	Bladder relaxation, sphincter closing		
M3	GI tract	Constipation, dry mouth		
	Ophthalmologic	Mydriasis		
M4	Brain	Balance impairment		
GERIATRIC PHARM	IACIST	GI - gastrointestinal		
BOOT C MP Adapted from Zimmerman K. 2015				


Urge UI Treatment Targets: Non-selective				
Receptor	Anatomical Location	Result of Antagonism		
	Brain	Cognitive impairment		
M1	GI tract	Constipation, dry mouth		
	Brain	Cognitive impairment		
M2	Heart	Tachycardia		
	Urinary tract	Bladder relaxation, sphincter closing		
	Urinary tract	Bladder relaxation, sphincter closing		
M3	GI tract	Constipation, dry mouth		
	Ophthalmologic	Mydriasis		
M4 Brain		Balance impairment		
€ GERIATRIC PHARMACIST BOOT C € MP Adapted from Zimmerman K. 2015.				


NOT .	Non-selective Anticholinergics					
Medication	Formulations	Adverse	Effects	Additional Comments		
Oxybutynin	IR tablets (Ditropan®)	MC	DST	Reference standard Gradual dose escalation		
	ER tablets (Ditropan XL®)			Better tolerated than IR		
	Patch (Oxytrol®)			OTC for women only Bypasses 1 st pass		
	Gel (Gelnique®)			Bypasses 1 st pass		
Tolterodine	IR tablets (Detrol®)			CYP2D6 > CYP3A4 metabolism Renal dose adjustments		
	ER capsules (Detrol [®] LA)			Better tolerated than IR		
Fesoterodine	ER tablets (Toviaz®)			Adjustments for renal impairment and 3A4 inhibitors		
Trospium	IR tablets (Sanctura®)			Dose adjustment for CrCl < 30 ml/min		
	ER tablets (Sanctura XR®)	LEA	AST	Better tolerated than IR Avoid in renal impairment		


Urge UI Treatment Targets: Selective					
Receptor Anatomical Location Result of Antagonism					
	Brain	Cognitive impairment			
M1	GI tract	Constipation, dry mouth			
	Brain	Cognitive impairment			
M2	Heart	Tachycardia			
	Urinary tract	Bladder relaxation, sphincter closing			
	Urinary tract	Bladder relaxation, sphincter closing			
M3	GI tract	Constipation, dry mouth			
	Ophthalmologic	Mydriasis			
M4 Brain		Balance impairment			
Geriatric pharmacist BOOT C MP Adapted from Zimmerman K. 2015					


Urge UI Treatment Targets: Selective				
Receptor	Anatomical Location Result of Antagonism			
	Brain	Cognitive impairment		
M1	GI tract	Constipation, dry mouth		
	Brain	Cognitive impairment		
M2	Heart	Tachycardia		
	Urinary tract	Bladder relaxation, sphincter closing		
	Urinary tract	Bladder relaxation, sphincter closing		
М3	GI tract	Constipation, dry mouth		
	Ophthalmologic	Mydriasis		
M4	Brain	Balance impairment		
GERIATRIC PHARMACIST Greatfrom Comp Adanted from Zimmerman K. 2015				


























Topical Vaginal Estrogen Products


Product	Regimen (for vulvar/vaginal atrophy)		
17β estradiol, vaginal tablet/insert; 10 mcg tablet (Vagifem [®] , Yuvafem [®]) 4 mcg, 10 mcg insert (Imvexxy [®])	1 tablet/insert intravaginally once daily for 2 weeks, then 1 tablet/insert twice weekly thereafter		
Conjugated equine estrogen vaginal cream; 0.625 mg/g (Premarin®)	0.325-1.25 mg (0.5-2 g cream) vaginally once daily (3 weeks of daily use, then 1 week off)		
Estradiol vaginal cream; 0.1 mg/g (Estrace [®])	2-4 g vaginally daily for 1-2 weeks, then reduce to $\%$ initial dose for 1-2 weeks; maintenance 1 g 1-3 times weekly		
17β estradiol vaginal ring; 2 mg (Estring®)	1 ring intravaginally every 3 months (delivers 7.5 mcg daily)		
Estradiol acetate vaginal ring; 12.4 or 24.8 mg (Femring [®])	1 ring intravaginally every 3 months (delivers 0.05 or 1 mg/day)		
ERIATRIC PHARMACIST BOOT C MP Cody ID et al. Cochrane Database Syst Rev. 2012 Oct 17:10:CD001405.			

49































American Urological Association Symptom Index
(AUASI)


In the past mont	h, how often have you experiend	ced the following symptoms?		
1. Sensation of not	completely emptying your bladder	Obstructive		
2. Need to urinate	less than two hours after urinating	Irritative		
3. Stopped and star	rted again while urinating	Obstructive		
4. Found it difficult	to postpone urination	Irritative		
5. Had a weak urina	ary stream	Obstructive		
6. Had to push or st	train to begin urinating	Obstructive		
7. How many times	do you get up at night to urinate?	Irritative		
	ll to 5 – all of the time; Question 7: e ild LUTS 0-7; Moderate to Severe LUT			
GERIATRIC PHARMACIST				







	Treatment Options for BPH/LUTS						
		a-blockers	PDE5	5ARI			
	MOA	Sphincter relaxation, bladder neck and prostate	Smooth muscle relaxation through increase in cAMP and cGMP	Blocks enzyme preventing testosterone and DHT from stimulating prostatic tissue			
	EFFICACY	 No significant difference in efficacy between non-selective (NS) and selective Lowers AUAIS by 4-6 points Starts within 1 week, but may take up to 4 weeks 	 Initially approved for ED 12-week trial of tadalafil showed AUASI reduction of 3.8 points 	 Similar efficacy between agents Reduction of prostate size by 25%, Improves AUASI by 4-5 points Works over 2-6 months Not recommended to prevent prostate cancer 			
	SIDE EFFECTS	Orthostatic hypotension, intraoperative floppy iris syndrome, caution in cardiovascular disease	Headache, indigestion, flushing, nasal congestion, orthostatic hypotension with a-blockers/ nitrates	Decreased libido, ED, gynecomastia			
	DUCTS		Tadalafil 5 mg daily (2.5 mg daily if CrCl 50-80, initial 2.5 mg daily if CrCl 30-50)	Finasteride 5 mg daily Dutasteride 0.5 mg daily			
	PRO			Combination product (Entadfi™) finasteride 5 mg/tadalafil 5 mg daily			
•	CAMP – cyclic adenosine monophosphate; GD- cyclic guanosine monophosphate; ED – erectile dysfunction (Langan RC. Prim Care Clin Office Pract. 2019;46:223-32. Fan Z, et al. Front Pharmacol. 2022 Mar 7;13:763184.						










Nomenclature for Kidney Disease						
Preferred Term	Explanation	Terms to avoid				
Kidney function and disease	Use "kidney" when describing kidney disease and function	Renal, "nephro-" (except in setting of specific diseases or syndromes)				
Kidney disease	Reflects the entirety of acute kidney diseases and disorders and chronic kidney disease	Renal disease, nephropathy (except in setting of specific disease or syndromes)				
Kidney failure (KF)	GFR < 15 ml/min per 1.73m ² or treatment by dialysis	Renal failure (RF); end-stage renal disease (ESRD); end-stage kidney disease (ESKD), renal disease, renal/kidney impairment, insufficiency, dysfunction, azotemia				
Kidney replacement therapy (KRT)	Includes dialysis and transplantations	Renal replacement therapy (RRT)				
Acute kidney diseases and disorders (AKD)	Disease duration ≤ 3 months, KDIGO definition	Acute renal failure (ARF); acute renal insufficiency (ARI)				
Acute kidney injury (AKI)	Subcategory of AKD, KDIGO Definition	ARF, ARI				
Chronic kidney disease (CKD)	KDIGO definition	Chronic renal failure, ESRD, renal/kidney impairment, insufficiency, dysfunction				
R – glomerular filtration rate; KDIGO –	Kidney Disease Improving Global Outcomes	Levey AS, et al. Kidney Int. 2020 Jun;97(6):1117-112				









Acute Kidney Injury • An acute rise in serum creatinine with or without a decrease in urine output over a short period of time KDIGO guideline definition: • Increase in SCr by ≥ 0.3 mg/dL within 48 hours; or • Increase in SCr to \geq 1.5 X baseline, which is known or presumed to have occurred within the prior 7 days; or • Urine volume < 0.5 mL/kg/hour for 6 hours • Types: • Prerenal = decreased blood flow • Intrinsic/intrarenal = structural damage (acute tubular necrosis, acute interstitial nephritis, glomerulonephritis) Postrenal = obstruction within urine collection system SCr – serum creatinine 605 Slide content modified with permission from MBartuca, LSylvia BOOT C[®]MP Levey AS, et al. Kidney Int. 2020 Jun;97(6):1117-1129.





	Treatment of AKI			Solid = appropriate at all stages Shaded = increasing priority as intensity increases			
	High Risk		Stage 1	Stage 2	Stage 3		
Discontinue all nephrotoxic agent when possible Ensure volume status and perfusion pressure Consider functional hemodynamic monitoring Monitor serum creatinine and urine output Avoid hyperglycemia Consider alternatives to radiocontrast procedures Non invasive diagnostic workup							
		Con	sider invasive diagnos	tic workup			
Stage	1	2	3	Check for changes in drug Consider KRT & ICU admiss			
SCr	SCr 1.5-1.9 X baseline OR ≥ 0.3 mg/dL ↑	2.0-2.9 X baseline	3.0 X baseline <u>OR</u> ↑ to ≥ 4 mg/dL <u>OR</u> start KRT		Avoid subclavian catheters if possible		
UO	< 0.5 mL/kg/hr for 6-12 hrs	< 0.5 mL/kg/hr for ≥ 12 hrs	< 0.3 mL/kg/hr for ≥ 24 hrs <u>OR</u> anuria for ≥ 12 hrs	KRT -	SCR – serum creatinine; UO – uri kidney replacement therapy; ICU – intensiw KDIGO. Kidney Inter. Suppl. 2012;	e care u	




	Р	Prognosis of CKD by GFR and albuminuria categories Adapted from KDIGO Kidney Int. Suppl. 2024;105(45) 5117-314. Green = low risk (if no other markers of kidney disease, no CKD); yellow = moderately increased risk; orange = high risk, red = very high risk; Numbers indicate frequency of monitoring (per year)			Persistent albuminuria categories Description and range		
CKD:					A1	A2	A3
Defined as abnormalities	Green = l				Normal to mildly increased	Moderately increased	Severely increased
of kidney structure/					< 30 mg/g < 3 mg/mmol	30-300 mg/g 3-30 mg/mmol	> 300 mg/g > 30 mg/mmol
function for > 3 months	3m²)	G1	Normal or high	≥ 90	1 if CKD	1	2
Classified by	(mL/min per 1.73m²) ion and range	G2	Mildly decreased	60-89	1 if CKD	1	2
<u>C</u> ause, <u>G</u> FR, and	egories (mL/min per 1 Description and range	G3a	Mildly to moderately decreased	45-59	1	2	3
<u>A</u> lbuminuria categories	ries (m	G3b	Moderately to severely decreased	30-44	2	3	3
	_ at	G4	Severely decreased	15-29	3	3	4 +
	3FR	G5	Kidney failure	< 15	4 +	4 +	4 +










	P	Prognosis of CKD by GFR and albuminuria categories			Persistent albuminuria categories Description and range			
CKD:					A1	F	2	A3
Defined as abnormalities	Green = l) Kidney Int. Suppl. 2024;105(4S) S117-314. low risk (if no other markers of kidney disease, no ellow = moderately increased risk; orange = high			Normal to mildly increased		erately eased	Severely increased
of kidney structure/	Numb	risk, red = very high risk; ers indicate frequency of monitoring (per year)		< 30 mg/g < 3 mg/mmol	30-300 mg/g 3-30 mg/mmol		> 300 mg/g > 30 mg/mmol	
function for > 3 months	3m²)	G1	Normal or high	≥90	1 if CKD		L	2
Classified by	ber 1.7 3 Inge	G2	Mildly decreased	60-89	1 if CKD		L	2
<u>C</u> ause, <u>G</u> FR, and	egories (mL/min per 1 Description and range	G3a	Mildly to moderately decreased	45-59	1		2	3
<u>A</u> lbuminuria categories	r ies (m l	G3b	Moderately to severely decreased	30-44	2		5	3
	년 GFR categories (mL/min per 1.73m ²) Description and range	G4	Severely decreased	15-29	3		3	4 +
	Geriatric pharmacist		Kidney failure	< 15	4 +	4	+	4 +















2023 AG	S Beers Criteria®	Table 6 includes list of medications to avoid or dose reduce for older adults		
Medications	Rationale	Recommendation	Strength of Recommendation	
Digoxin for first-line treatment of atrial fibrillation or heart failure	Decreased renal clearance of digoxin may lead to increased risk of toxic effects	Avoid dosages > 0.125 mg/day (may require further dose reduction CKD G4 and G5)	Strong (moderate quality evidence)	
Trimethoprim- sulfamethoxazole	Increased risk of hyperkalemia when used concurrently with an ACEI or ARB in presence of decreased CrCI	Use with caution in patients on ACEI or ARB and decreased CrCl Reduce dose if CrCl 15-29, avoid if < 15 mL/min	Strong (low- moderate quality evidence)	
Nitrofurantoin	Potential for pulmonary toxicity, hepatotoxicity, and peripheral neuropathy, especially with long-term use	Avoid in individuals with CrCl < 30 mL/min or for long-term suppression	Strong (low quality evidence)	
NSAIDs	May increase risk of acute kidney injury and further decline of kidney function	Avoid in individuals with CrCl < 30 mL/min	Strong (moderate quality evidence)	
GERIATRIC PHARMACIST Slide content modified from JBlack, CWhittaker bps BOOT C*MP AGS Beers Criteria* Update Expert Panel. J Am Geriatr Soc. 2023 Jul;71(7):2052-81.				

Medication Class	Agents	Renal Considerations	
Antihypertensives/	Beta blockers (e.g., atenolol)	Increase drug exposure, risk of toxic effect as renal function declines	
ardiac medications	Digoxin	Adjust in the setting of acute/chronic decline, or change in health status	
	Diuretics	Thiazide diuretics decreased efficacy eGFR < 30 mL/min/1.73m ²	
Antihyperglycemics	Sulfonylureas Insulin	Increase risk of hypoglycemia as renal function declines, other hypoglycemics Adjust in the setting of acute/chronic decline, or change in health status	
	Metformin	Increase risk of lactic acidosis in setting of AKI, eGFR < 30 mL/min/1.73m ²	
Pain/analgesics	NSAIDs (generally avoid)	Hyperkalemia, increased risk of AKI, increase blood pressure	
	Tramadol	Opioid-like adverse effects, short-term use, avoid extended release	
	Gabapentin, pregabalin	Increased risk of toxic effects as function declines	
Acid Suppressants	Proton pump inhibitors (PPI)	Chronic PPI use associated with AKI and CKD	
	H2-receptor antagonists	Accumulation and increased risk of adverse effects with usual dosing in setting of acute/chronic decline	
Other	Allopurinol	Allopurinol hypersensitivity syndrome: recent onset, diuretic therapy Start low (50 – 100 mg daily) then titrate to uric acid goal	









References

U

Johnson TM 2nd, Vaughan CP. Urological function and dysfunction in aging: Diagnosis and treatment. Handb Clin Neurol. 2019;167:495-509.

Guzzo TJ, Drach GW. Major urologic problems in geriatrics: assessment and management. Med Clin North Am. 2011 Jan;95(1):253-64. doi: 10.1016/j.mcna.2010.08.026. PMID: 21095428.

Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. Urinary Incontinence in Women: A Review. JAWA. 2017 Oct 24;318(16):1592-1604. doi: 10.1001/jama.2017.12137. PMID: 29067433.

Subak LL, Wing R, West DS, et al. PRIDE Investigators. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med. 2009 Jan 29;360(5):481-90. doi: 10.1056/NEIMoa0806375.

Dallosso HM, McGrother CW, Matthews RJ, et al. Leicestershire MRC Incontinence Study Group. The association of diet and other lifestyle factors with overactive bladder and stress incontinence: a longitudinal study in women. BIU Int. 2003.Jul;92(1):69-77.

Dumpulin C, Hay-Smith EJ, Mar, Habés-Séguin G, Relvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev. 2014 May 14(S)(CD005654. doi: 10.1002/14651858.CD005654.put3.

Zimmerman K. Medications for Urinary Incontinence: Worth a Drop? 5th Annual Interdisciplinary Senior Care Symposium. October 22, 2015.

Shamiyan T, Wyman JF, Ramakrishnan R, et al. Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review. Ann Intern Med. 2012 Jun; 156(12):861-74. Effective Health Care Program. Nonsurgical Treatments for Urinary Incontinence in Adult Womer: Dagnosis and Comparative Effectiveness. Spensory for Healthcare Research Quality 2012. Available at: http://effectivelence.aturg.op/eff.condocit/15/19/10/21/RSB Urinary/incontinence.gencesmmpd (Recessed in Nonsurfer 19, 2012).

Machuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012 Jan 18;1:CD005429. doi: 10.1002/14651858.CD005429.pub2. PMID: 22258963.

Woodford HJ. Anticholinergic Drugs for Overactive Bladder in Frail Older Patients: The Case Against. Drugs Aging. 2018 Sep;35(9):773-776. doi: 10.1007/s40266-018-0575-x. PMID: 30097908. Mirabagron (package insert). Northbrook, IL: Astellas Pharma US, Inc.; 2018.

Staskin D, Frankel J, Varano S, et al. International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluation the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR. J Urol. 2020 Aug;204(2):316-324. doi: 10.1097/IU.00000000000807.


Rechberger T. Wróbel A. Evaluating vibegron for the treatment of overactive bladder. Expert Opin Pharmacother. 2021 Jan: 22(1):9-17.


Vibegron (package insert). Irvine, CA: Urovant Services, Inc; 2020.


89


References


5	Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Injury. Kidney Injury.
ł	Levey AS. Defining AKD: The Spectrum of AKI, AKD, and CKD. Nephron. 2022;146(3):302-305. doi: 10.1159/000516647. Epub 2021 Jun 24. PMID: 34167119.
2	Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2024 Clinical Practice Guideline for the Management of Chronic Kidney Disease. Kidney Int. Suppl. 2024;105(45) 5117-314.
	Evans M, Lewis RD, Morgan AR, Whyte MB, Hanif W, Bain SC, Davies S, Dashora U, Yousef Z, Patel DC, Strain WD. A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives. Adv Ther. 2022 Jan;39(1):33-43. doi: 10.1007/s12325-021-01327-z. Epub 2021 Nov S. PMID: 34739697; PMIDI: PMIC8569052.
8	Delgado C, Powe NR. Resolving the Debate: The Future of Using Race in Estimating Kidney Function. Adv Chronic Kidney Dis. 2022 Jan;29(1):5-16. doi: 10.1053/j.ackd.2022.001. PMID: 35690404
8	Perre CC, Marzinke MA, Ahmed SB, Collister D, Colón-Franco JM, Hoenig MP, Lorey T, Palevsky PM, Palmer OP, Rosas SE, Vassalotti J, Whitley CT, Greene DN. AACC/NKF Guidance Document on Improving Equity Dronic Kidney Disease Care. J Appl Lab Med. 2023 Jul 5;8(4):789-816. doi: 10.1093/jaim/jfa0022.
8	Hart LA, Anderson GD. Methods of Estimating Kidney Function for Drug Dosing in Special Populations. Clin Pharmacokinet. 2018 Aug;57(8):943-976. doi: 10.1007/s40262-018-0628-7. PMID: 29357102.
8	Daisley-Kydd RE, Mason NA. Calcitriol in the management of secondary hyperparathyroidism of renal failure. Pharmacotherapy. 1996 Jul-Aug;16(4):619-30. PMID: 8840368.
8	By the 2023 American Geriatrics Society Beers Criteria [®] Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria [®] for potentially inappropriate medication use in older adults. J Am Senatr Soc. 2023 July 71(7):2052-2081. doi: 10.1111/jgs.18372. Epub 2023 May 4.
2	Kidney Disease: Improving Global Outcomes (KDIGO). Other complications of CKD. Kidney Int. 2013;3(1)91-111.
	Nagge J, Crowher M, Hrsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med. 2002 Dec 9-23;162(22):2605-9. doi: 10.1001/archinte: 162.22.2605. PMID: 12456233.
-	Dalbeth N. Sarro L. Alforurinol dosing in remal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial. 2007 Sep-Oct;20(5):391-5. doi: 10.1111/j.1525- 3992.2007.00270.x. AVID: 19.97242.
1	Moledina DG, Perazella MA. Proton Pump Inhibitors and CKD. J Am Soc Nephrol. 2016 Oct;27(10):2926-2928. doi: 10.1681/ASN.2016020192. Epub 2016 Apr 14. PMID: 27080978; PMCID: PMC5042680.
	Wanlucu J, Tonelli M, Ray JG, Papaicannou A, Youssef G, Thiessen-Philbrook HR, Holbrook A, Garg AX. Dose-reducing H2 receptor antagonists in the presence of low glomerular filtration rate: a systematic review of the evidence. Nachrol Dial Transplant. 2005 Nov.20(11):2376-84. doi: 10.1093/ndt/pH025. Epub 2005 Aug 9. PMID: 16091377.























	RIFLE Category	SCr and GFR Criteria	Urine Output Criteria
	Risk	SCr increase to 1.5-fold or GFR decrease >25% from baseline	<0.5 mL/kg/hr for ≥6 hours
	Injury	SCr increase to twofold or GFR decrease >50% from baseline	<0.5 mL/kg/hr for ≥12 hours
	Failure	SCr increase to threefold or GFR decrease >75% from baseline, or SCr \geq 4 mg/dL (354 µmol/L) with an acute increase of at least 0.5 mg/dL (44 µmol/L)	Anuria for ≥12 hours
Compare:	Loss	Complete loss of function (RRT) for >4 weeks	1
	ESRD	RRT >3 months	
RIFLE,	AKIN Criteria	SCr Criteria	Urine Output Criteria
	Stage 1	SCr increase ≥0.3 mg/dL (27 µmol/L) or 1.5- to 2-fold from baseline	<0.5 mL/kg/hr for ≥6 hours
AKIN,	Stage 2	SCr increase >2- to 3-fold from baseline	<0.5 mL/kg/hr for ≥12 hours
KDIGO	Stage 3	SCr increase >3-fold from baseline, or S ^{cr} \ge 4 mg/dL (354 µmol/L) with an acute increase of at least 0.5 mg/dL (44 µmol/L), or need for RRT	<0.3 mL/kg/hr for ≥24 hours or anuria for ≥12 hours
	KDIGO Criteria	SCr Criteria	Urine Output Criteria
	Stage 1	SCr increase ≥0.3 mg/dL (27 μmol/L) or 1.5-1.9 times from baseline	<0.5 mL/kg/hr for 6-12 hours
	Stage 2	SCr increase 2-2.9 times from baseline	<0.5 mL/kg/hr for ≥12 hours
	Stage 3	SCr increase three times from baseline, or SCr ≥ 4 mg/dL (354 µmol/L), or need for RRT, or eGFRc <35 mL/min/1.73 m ² (0.34 mL/s/m ²) in patients <18 years	Anuria for ≥12 hours
	т •		

Differentiating Between Causes of AKI							
LABORATORY TEST	PRERENAL	INTRARENAL	POSTRENAL				
BUN/SCr	20:1 ratio SCr doubles BUN will rapidly increase (usually will go up faster than creatinine)	16:1 ratio SCr doubles BUN increases but not as fast or to the same extent as prerenal	~16:1 ratio				
Urine output	Usually \downarrow output because trying to conserve but not indicative of poor prognosis	Low/normal output; lower output is a poor prognostic sign	Low/normal output; lower output is a poor prognostic sign				
Urine sediment	Normal/bland sediment with no evidence of cell death	ATN: Granular cell casts from PCT called "muddy brown casts" AIN: WBC-coated casts +/- eosinophilic casts Glomerulonephritis: RBC casts	Cellular debris (depends on back pressure and development of ATN)				
Urinary RBC	None	2-4 + (in glomerulonephritis)	Variable				
Urinary WBC	None	2-4 + (in AIN)	1+				
Urine Na	< 20 mEq/L	> 40 mEq/L	> 40 mEq/L				
Urine protein	None	In all intrarenal AKIs; highest in glomerulonephritis	Variable				
FeNA (%)	< 1% (conserving Na)	≥ 2% (wasting Na)	≥ 2% (wasting Na)				